ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.59
1.05%
US Tech 100
20,332.80
1.61%
S&P 500
5,954.50
1.59%
US Dollar vs CAD
1.4438
-0.20%
Bitcoin
93,147.90
8.29%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Immunome Inc (IMNM) Share Price

Immunome Inc

Immunome Inc (IMNM)

NASDAQ
9.40
0.51
(5.74%)
Closed March 02 3:00PM
Delayed by 15 minutes
9.4011
0.0011
(0.01%)
After Hours: 6:59PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
9.40
Bid
8.50
Ask
15.00
Volume
880,594
8.67 Day's Range 9.44
8.86 52 Week Range 30.958
Market Cap
586.718M
Previous Close
8.89
Open
8.69
Last Trade
1
@
9.41
Last Trade Time
Financial Volume
US$ 7,971,771
VWAP
9.0527
Average Volume (3m)
931,712
Shares Outstanding
62,416,845
Dividend Yield
-
PE Ratio
-5.50
Earnings Per Share (EPS)
-1.71
Revenue
14.02M
Net Profit
-106.81M

About Immunome Inc

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.immunome.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was US$8.89. Over the last year, Immunome shares have traded in a share price range of US$ 8.86 to US$ 30.958.

Immunome currently has 62,416,845 shares outstanding. The market capitalization of Immunome is US$554.89 million. Immunome has a price to earnings ratio (PE ratio) of -5.50.

Ask ADVFN Intelligence (AI)

IMNM Latest News

More News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
February 03 2025
IMNM (5.74%)

Form 8-K - Current report
Edgar (US Regulatory)
January 30 2025
IMNM (5.74%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
January 30 2025
IMNM (5.74%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
January 29 2025
IMNM (5.74%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.84-8.20312510.2410.478.866993939.43386502CS
4-1.14-10.815939278910.5412.448.86102469110.54778261CS
12-3.43-26.734216679712.8315.1258.8693171210.79887903CS
26-5.51-36.955063715614.9116.738.8683835311.80182142CS
52-16.66-63.929393706826.0630.9588.8679097713.90578629CS
1562.8844.17177914116.5230.9582.0935673213.40761425CS
260-6.26-39.974457215815.6663.782.0930332815.19598305CS

IMNM - Frequently Asked Questions (FAQ)

What is the current Immunome share price?
The current share price of Immunome is US$ 9.40
How many Immunome shares are in issue?
Immunome has 62,416,845 shares in issue
What is the market cap of Immunome?
The market capitalisation of Immunome is USD 554.89M
What is the 1 year trading range for Immunome share price?
Immunome has traded in the range of US$ 8.86 to US$ 30.958 during the past year
What is the PE ratio of Immunome?
The price to earnings ratio of Immunome is -5.5
What is the cash to sales ratio of Immunome?
The cash to sales ratio of Immunome is 41.9
What is the reporting currency for Immunome?
Immunome reports financial results in USD
What is the latest annual turnover for Immunome?
The latest annual turnover of Immunome is USD 14.02M
What is the latest annual profit for Immunome?
The latest annual profit of Immunome is USD -106.81M
What is the registered address of Immunome?
The registered address for Immunome is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Immunome website address?
The website address for Immunome is www.immunome.com
Which industry sector does Immunome operate in?
Immunome operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAKSTAK Inc
US$ 3.97
(156.13%)
174.23k
ORGOOrganogenesis Holdings Inc
US$ 6.21
(102.28%)
59M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.57M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.18M
ARBBARB IOT Group Ltd
US$ 0.6635
(38.23%)
59.08M
NVNINVNI Group Ltd
US$ 0.99
(-50.50%)
72.79M
SPGCSacks Parente Golf Inc
US$ 0.2085
(-48.65%)
58.21M
ADGMAdagio Medical Holdings Inc
US$ 0.8081
(-47.53%)
756.76k
PRAXPraxis Precision Medicines Inc
US$ 38.60
(-40.64%)
3.2M
SAGSAG Holdings Ltd
US$ 1.19
(-38.97%)
789.86k
NVDANVIDIA Corporation
US$ 124.92
(3.97%)
389.48M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.44
(7.78%)
154.46M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.18M
LCIDLucid Group Inc
US$ 2.22
(-0.45%)
136.17M

IMNM Discussion

View Posts
tw0122 tw0122 3 months ago
Looking good in some reverse head and shoulders at .85+4% and  .92-.99 up next. The world of DNA
👍️0
Monksdream Monksdream 6 months ago
IMNM under $15

👍️0
Monksdream Monksdream 11 months ago
IMNM 10Q due 3/22
👍️0
Monksdream Monksdream 12 months ago
IMNM new 52 week hi
👍️0
Monksdream Monksdream 1 year ago
IMNM new 52 week high
👍️0
OncoJock OncoJock 1 year ago
Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ
👍️0
OncoJock OncoJock 1 year ago
agree
👍️0
Laster Laster 1 year ago
Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.
👍️ 1
Laster Laster 1 year ago
I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.
👍️ 1
wiwineguy wiwineguy 2 years ago
Ha, sold in fall of 21 for $25.
👍️0
makinezmoney makinezmoney 2 years ago
$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa


Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies



GO $IMNM
👍️0
makinezmoney makinezmoney 2 years ago
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50


Offfffffffffff she goes.

Nice boomer



GO $IMNM
👍️0
Awl416 Awl416 2 years ago
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
👍️ 1
wiwineguy wiwineguy 4 years ago
you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu
👍️0
Harbor6460 Harbor6460 4 years ago
They cannot dilute on the bid. Only the ask
👍️0
Pedro2004 Pedro2004 4 years ago
Pulled down to under $20.00
👍️0
Pedro2004 Pedro2004 4 years ago
They pulled this down to under $21.00

I'm back-in at $21.00
👍️0
Major_Bankz Major_Bankz 4 years ago
$22.50 U worry too much, should be $25+ this afternoon IMO
👍️0
Pedro2004 Pedro2004 4 years ago
I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.
👍️0
Pedro2004 Pedro2004 4 years ago
This run could have broke $30 today. But the company killed-it.
👍️0
Major_Bankz Major_Bankz 4 years ago
yep, shorties portfolio will get destroyed here.
👍️0
Pedro2004 Pedro2004 4 years ago
The dilution is going to kill this run.
👍️0
Pedro2004 Pedro2004 4 years ago
Looks like the company is dumping shares on the bid.
👍️0
Major_Bankz Major_Bankz 4 years ago
I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO
👍️0
Major_Bankz Major_Bankz 4 years ago
Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO
👍️0
Major_Bankz Major_Bankz 4 years ago
Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.
👍️0
Major_Bankz Major_Bankz 4 years ago
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
👍️0

Your Recent History

NASDAQ
IMNM
Immunome
NASDAQ
FBRAX
Agf Global Select Fund M...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads